CareDx Director Hannah Valantine's Stock Transactions Under Rule 10b5-1 Plan

This Form 4 filing reports two significant stock transactions by CareDx director Hannah Valantine. On June 12, 2026, Valantine acquired 9,795 shares of CareDx common stock through restricted stock unit vesting at $0 per share, increasing her holdings to 48,789 shares. Three days later on June 15, 2026, she sold 12,103 shares at a weighted average price of $23.1123 per share under a Rule 10b5-1 trading plan adopted in December 2025. The sale reduced her holdings to 36,686 shares. The transactions represent both equity compensation vesting and planned disposition of shares, with the sale executed pursuant to a pre-established trading plan that provides legal protection against insider trading allegations. The filing includes a power of attorney authorizing company representatives to file Section 16 reports on Valantine's behalf.